90K/ LGALS3BP Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection

Laure Bosquillon de Jarcy, Bengisu Akbil, Johanna Leyens, Dylan Postmus, Greta Harnisch, Jenny Jansen, Marie Luisa Schmidt, Annette Aigner, Fabian Pott, Robert Lorenz Chua, Lilian Krist, Roberta Gentile, Barbara Mühlemann, Terry C. Jones, Daniela Niemeyer, Julia Fricke, Thomas Keil, Tobias Pischon, Jürgen Janke, Christian Conrad, Stefano Iacobelli, Christian Drosten, Victor M. Corman, Markus Ralser, Roland Eils, Florian Kurth, Leif Erik Sander, Christine GoffinetmedRxiv 2022 · DOI

TL;DR

Researchers found that the protein 90K (LGALS3BP), a known broad-spectrum antiviral, is significantly upregulated in the blood of COVID-19 patients, particularly those with severe disease. However, despite its high levels in patients, laboratory experiments reveal that 90K fails to effectively restrict SARS-CoV-2 infection, suggesting it acts as a marker of the immune response rather than a direct defense mechanism.

What Problem Does This Paper Address?

When the body detects a viral intruder, it releases interferons, which act as "alarm bells" that trigger the expression of hundreds of Interferon-Stimulated Genes (ISGs). One such gene, LGALS3BP, produces a secreted glycoprotein called 90K. In the past, 90K has shown impressive antiviral chops, interfering with the maturation of HIV-1 and helping mice survive the flu.

Given its track record, the authors wanted to know: Is 90K part of our natural defense against SARS-CoV-2? Does its expression correlate with how sick a patient gets? And most importantly, could we use it—or a drug that mimics it—to stop the virus in its tracks?

Methods

The team employed a multi-pronged approach combining clinical data with "wet lab" molecular biology:

  • Clinical Cohort: They analyzed serum and peripheral blood mononuclear cells (PBMCs) from 44 hospitalized COVID-19 patients at Charité – Universitätsmedizin Berlin, comparing them to age- and sex-matched healthy controls.
  • Protein & RNA Analysis: They used ELISAs to measure 90K protein levels in blood and qRT-PCR to track mRNA levels in cells.
  • Data Mining: They "re-mined" existing single-cell RNA sequencing (scRNA-seq) datasets from other COVID-19 studies to see exactly which cell types were pumping out LGALS3BP mRNA.
  • Functional Assays: To test if 90K actually stops the virus, they overexpressed the protein in various cell lines (HEK293T, Caco-2) and even added purified 90K protein directly to virus stocks to see if it inhibited infection.

Datasets

The study utilized several key resources:

  • PaCOVID-19 Study: A prospective cohort of COVID-19 patients in Berlin.
  • NAKO Health Study: Used for healthy control samples.
  • Dual Center Cohort (scRNA-seq): A published dataset (Schulte-Schrepping et al., 2020) used to analyze PBMC gene expression at single-cell resolution.
  • Respiratory scRNA-seq: A published dataset (Chua et al., 2020) used to look at gene expression in the actual site of infection (the lungs/airways).

Key Insights and Ideas

  • The Secretion Signature: While 90K levels were sky-high in the serum (the liquid part of the blood), the levels inside the immune cells (PBMCs) were actually lower than in healthy controls. This suggests that SARS-CoV-2 infection triggers a massive "secretion event," where cells dump their 90K stores into the extracellular space.
  • Monocytes are the Factories: The scRNA-seq data revealed that monocytes, dendritic cells, and plasmablasts are the primary sources of LGALS3BP mRNA in the blood during infection.
  • A Silent Site of Infection: Interestingly, while 90K goes up in the blood, it doesn't seem to be upregulated in the respiratory tract—the primary battlefield where the virus replicates. This suggests the virus might have evolved ways to evade or suppress this specific immune response in the lungs.
  • Ineffective Defense: Despite its success against HIV and Flu, 90K was largely a "bystander" here. While it showed a very mild inhibitory effect in one specific engineered cell line (HEK293T/ACE2), it failed to stop the virus in more natural lung-derived cells.

Key Results

  • Biomarker Potential: Serum 90K levels were significantly higher in COVID-19 patients than controls ($p < 0.0001$). Levels were highest in patients with severe disease (WHO grade 5) and declined as patients recovered.
  • No Direct Restriction: In Caco-2 cells (a standard model for infection), overexpressing 90K did not reduce viral RNA or the production of viral proteins (Spike and Nucleocapsid).
  • Exogenous Failure: Adding purified 90K protein to cells or virus stocks failed to modulate the infectivity of SARS-CoV-2 particles.
  • Conclusion: 90K is a "prototypic ISG"—it’s a great indicator that the interferon system is active, but it isn't an active component of the antiviral shield against this specific coronavirus.

Limitations and Future Work

The authors acknowledge that their PBMC sample size was relatively small ($n=12-14$). Furthermore, while 90K doesn't directly stop the virus from entering cells, it might have "immunomodulatory" roles—like activating Natural Killer (NK) cells—that weren't captured in these simplified cell culture models.

Future research could investigate whether 90K contributes to the "cytokine storm" seen in severe cases or if it could serve as a reliable prognostic biomarker to predict which patients are at risk of declining.

Summary updated

Abstract

Abstract Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP , displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Here, we analyzed the expression of 90K/ LGALS3BP in 44 hospitalized COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/ LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties.
BibTeX
@misc{jarcy2022k,
  author = {Laure Bosquillon de Jarcy and Bengisu Akbil and Johanna Leyens and Dylan Postmus and Greta Harnisch and Jenny Jansen and Marie Luisa Schmidt and Annette Aigner and Fabian Pott and Robert Lorenz Chua and Lilian Krist and Roberta Gentile and Barbara Mühlemann and Terry C. Jones and Daniela Niemeyer and Julia Fricke and Thomas Keil and Tobias Pischon and Jürgen Janke and Christian Conrad and Stefano Iacobelli and Christian Drosten and Victor M. Corman and Markus Ralser and Roland Eils and Florian Kurth and Leif Erik Sander and Christine Goffinet},
  title = {{90K/ <i>LGALS3BP</i> Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection}},
  year = {2022},
  doi = {10.1101/2022.07.18.22277255},
  howpublished = {medRxiv},
}
Figure